Shots:
- The US FDA has granted Fast Track Designation (FTD) to SOT106 for the treatment of soft tissue sarcoma
- SOT106 is an ADC that targets LRRC15, a clinically validated target broadly expressed across multiple prevalent sarcoma subtypes, & has received FDA Orphan Drug Designation for osteosarcoma treatment
- SOTIO plans to initiate a first-in-human clinical trial of SOT106 later this year
Ref: Globenewswire | Image: SOTIO Biotech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
